An association between certain clinical conditions may remain unrecognised for years. There are many ways with which the skin and other systems are linked. Examination of the skin may help the clinician in assessing systemic disease: many patients with dermatitis herpetiformis have intestinal malabsorption and patients with vitiligo show an increase of organ-specific autoimmune diseases.' During our investigation into a new approach to the treatment of facial flushing in rosacea we found three consecutive patients who not only had rosacea but also migraine. This stimulated us to attempt to establish the association between the two conditions.
Methods and results
One hundred and thirty-seven patients with rosacea and 161 controls were asked whether they had migraine. The control group were predominantly fit hospital personnel; a few had either viral warts, basal cell carcinoma, or gravitational eczema. The definition of migraine was episodic vascular headache with at least two of the following features: unilateral headache; associated nausea or vomiting; visual aura; family history of migraine; and past history of bilious attacks. 
Discussion
We know of no report in which the association between migraine and rosacea has been described. Crawford3 reported a 29-year-old woman with migraine who had an unusual eruption and flushing of the right leg, occurring independently of headaches, possibly representing a cutaneous equivalent. Facial migraine-which consists of episodic facial neuralgia, flushing, and reddening of the skin and lachrymation-usually occurs in middle-aged women with a past history of migraine4; the presence or absence of rosacea has not been reported in these patients.
The incidence of migraine in our controls is higher than that in other control series.5 Thus our observation that 44%O of patients with rosacea suffered from migraine is significant when compared with not only our own but also other control series. The association between rosacea and migraine is not surprising, since both are associated with abnormal vascular reactivity, and both are aggravated by stress.
Although migraine tends to occur in younger patients than rosacea, this lack of a temporal relationship does not make the association less likely because it is also seen in other conditions such as eczema and asthma.
The association between rosacea and migraine has several implications. The presence of rosacea may help clinicians in diagnosing migraine variants. Oral contraceptives may significantly increase the frequency and severity of headaches in migrainous women, and hence should patients with rosacea avoid them ? Some patients with migraine develop their attacks after eating cheese or chocolate because of failure to metabolise such compounds as tyramine or phenylethylamine. Do such factors aggravate rosaceous flushing? Study of the facial blood vessels in rosacea may help to understand better the physiological and biochemical abnormalities of the intracranial, extracerebral blood vessels of migraine. Conversely, could drugs prescribed for migraine help facial flushing in rosacea ? In low doses clonidine reduces facial flushing and helps migraine at the menopause, and our preliminary investigations show that clonidine probably helps in reducing the facial erythema and flushing of rosacea.
We thank Dr Intestinal obstruction complicating orphenadrine treatment
Gastrointestinal symptoms associated with drugs are common in clinical practice and may take several forms. A reduction in bowel motility with consequent constipation may be caused by drugs with an atropine-like action, including anti-Parkinsonian agents. Parkinsonism itself may cause constipation,' and treatment with a constipation-provoking agent might be expected to produce troublesome symptoms. Severe constipation is perhaps less common than would be predicted but can occasionally be severe enough to cause intestinal obstruction.2 A case is presented here in which orphenadrine appears to have precipitated such an event, an association not previously reported.
Case report
The patient was a 77-year-old man who was diagnosed as suffering from Parkinsonism in 1972, when immobile facies, bradykinesia, and a typical tremor were noted. Orphenadrine was started at a dose of 50 mg three times a day, which improved his symptoms. In 1973 an episode of urinary retention was treated by transurethral resection of the prostate, with complete resolution ofurinary symptoms. He presented on this occasion with a two-week history of abdominal distension with vomiting for three days. He had the signs of intestinal obstruction but was not acutely ill. Rectal examination showed an empty rectum and a normal prostate. Sigmoidoscopy to 25 cm was normal but clear bubbly mucus was seen coming from above. Plain x-ray examination of the abdomen showed a few fluid levels and barium enema examination suggested carcinoma of the sigmoid colon.
After a defunctioning colostomy a formal laparotomy was performed. Rock-hard faeces were impacted in the sigmoid colon and extended back to the caecum. Manual removal by a colotomy was carried out, after which there was no evidence of carcinoma or any other mural lesion in the colon.
Discussion
This man had a clinical and radiological syndrome which exactly resembled carcinoma of the colon. The very severe constipation was probably precipitated by orphenadrine. This drug was probably additionally implicated in the patient's previous urinary retention. Most anti-Parkinsonian agents have atropinic properties, and the smooth muscle relaxation so produced leads to bowel stasis. Warnes et al2 have described six patients in a psychiatric institution who developed intestinal obstruction caused by impacted faeces. All had been taking atropinic anti-Parkinsonian agents as well as their phenothiazine treatment.
Orphenadrine is structurally dissimilar to other anti-Parkinsonian agents and is related to diphenhydramine hydrochloride. 
Methods and results
Ten healthy non-obese men aged between 18 and 25 years volunteered for study. They reported on each of two mornings 72 hours apart, having fasted for 12 to 16 hours, and lay semi-recumbent during the study. After 30 minutes' rest two basal venous blood samples were withdrawn and a 4-mg tablet of salbutamol or of placebo was given orally, in random order. Further venous samples were withdrawn after 30, 60, and 120 minutes, and each sample was assayed for plasma levels of insulin (immunoassay), glucose (glucose oxidase method), NEFA (measured as palmitic acid with the Duncombe colorimetric technique), free glycerol and triglyceride (enzymatic method), and potassium (flame photometry).
There was a small but significant sustained increase in plasma insulin after salbutamol, with a more gradual increase in glucose (see table) . No such changes occurred after placebo. Plasma NEFA and free glycerol levels increased slowly after both salbutamol and placebo, but the NEFA increase occurred earlier (at 60 minutes) after salbutamol. After salbutamol plasma potassium concentrations decreased progressively from the basal level of 4-1 ± 0 1 mmol/l (4-1 ± 0 1 mEq/l), but the fall was statistically significant only at the 120-minute level (3-9 ± 0-1 mmol/l, P < 0 05). Plasma triglyceride levels were unchanged.
Changes in plasma constituents after salbutamol or placebo (mean ± SEM)
